## Purpose: To perform comparison of gadolinium-enhanced and ferumoxides-enhanced magnetic resonance imaging (mri) in the detection of nodule-in-nodule appearance of hepatocellular carcinomas (hccs). ## Materials and methods: During a recent 45-month period, we had eight patients (five men and th
Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging
✍ Scribed by Masahiro Okada; Yasuharu Imai; Tonsok Kim; Sachiyo Kogita; Manabu Takamura; Seishi Kumano; Hiromitsu Onishi; Masatoshi Hori; Kazuto Fukuda; Norio Hayashi; Kenichi Wakasa; Michiie Sakamoto; Takamichi Murakami
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 564 KB
- Volume
- 32
- Category
- Article
- ISSN
- 1053-1807
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Purpose
To compare enhancenent patterns of hepatocellular carcinoma (HCC) and dysplastic nodule (DN) between gadoxetate‐ and ferucarbotran‐enhanced MRI.
Materials and Methods
Patients recruited from ultrasound surveillance for HCC in chronic liver diseases were enrolled in this prospective study approved by institutional review board. Thirty‐six patients with 37 histologically proven HCC, including 22 well‐differentiated HCCs (wHCC), 15 moderately to poorly differentiated HCCs (mpHCCs), and 4 DNs, underwent gadoxetate‐enhanced and ferucarbotran‐enhanced MRI. We compared hepatobiliary phase image of gadoxetate‐enhanced MRI with ferucarbotran‐enhanced MR image regarding signal intensity of HCC and DN relative to surrounding liver parenchyma. We calculated contrast ratios between tumor and liver on pre‐enhancement, hepatobiliary phase of gadoxetate‐enhanced MRI and ferucarbotran‐enhanced MRI.
Results
On ferucarbotran‐enhanced MRI, all mpHCCs showed hyper‐intensity, while 14 wHCCs (14/22;63%) showed iso‐intensity. On hepatobiliary phase of gadoxetate‐enhanced MRI, 13 mpHCCs (13/15;86%) and 20 wHCCs (20/22;91%) showed hypo‐intensity. Two DNs and the other two showed iso‐ and hypo‐intensity, respectively, on gadoxetate‐enhanced MRI, whereas all DNs revealed iso‐intensity on ferucarbotran‐enhanced MRI. Gadoxetate‐postcontrast ratio was significantly lower than ferucarbotran‐postcontrast ratio in wHCC (P = 0.015).
Conclusion
The uptake function of hepatocytes that are targeted by gadoxetate is more sensitive than that of Kupffer cells targeted by ferucarbotran in stepwise hepatocarcinogenesis. J. Magn. Reson. Imaging 2010;32:903–913. © 2010 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract ## Purpose To intraindividually compare the enhancement pattern of focal nodular hyperplasia (FNH) after dynamic administration of two bolus‐injectable liver‐specific MR contrast agents, ferucarbotran and gadobenate dimeglumine. ## Materials and Methods A total of 19 patients with 24
## Abstract ## Purpose To assess the relationship between lesion size and MR imaging findings of pathologically‐proven hepatocellular carcinoma (HCC). ## Materials and Methods In a retrospective, single‐center study, 37 consecutive patients were identified between 1999 and 2005 that underwent pr
## Purpose: To investigate the image quality and detection rate of focal liver lesions by comparing a t2-weighted breath-hold single-shot sequence and a t2-weighted high spatial resolution fast spin-echo sequence with respiratory triggering via unenhanced and superparamagnetic iron oxide (spio)-enh